Myriad Genetics, Tufts Health Plan Sign 3-Year Contract to Cover Prolaris for Members With Localized Prostate Cancer

Myriad Genetics, Inc.

today announced that it has signed a three-year contract with Tufts Health Plan through which the plan will provide coverage of Prolaris® for members diagnosed with localized prostate cancer. Prolaris is the first and only biopsy test validated against prostate cancer specific mortality. Tufts Health Plan is a leading health plan in the Northeast with more than one million members. Tufts Health Plan's members will benefit from this agreement, which is designed to drive optimal treatment because men can confidently pursue active surveillance for tumors identified as being less aggressive with Myriad's extensively validated Prolaris combined score. Recent data show that many men realize no benefit from interventional treatment, and many suffer needlessly from the side effects associated with radical prostatectomy and radiation. "Myriad is excited to offer Prolaris testing to Tufts Health Plan's members. We believe it will help to improve patient care and lower healthcare costs," said Nicole Lambert, general manager, Urology Business Unit, Myriad Genetic Laboratories. "The Prolaris test has been validated in multiple clinical studies and provides substantially stronger prognostic power than standard pathology. The Prolaris test enables physicians to confidently tailor treatment plans